GlassScriptPhysician profile
Tami Lee Bach
NPI 1306887245
$25,119.21
in general payments reported to CMS, 2019-2025
26 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,551 · 2020: $3,201 · 2021: $8,996 · 2022: $509 · 2023: $3,973 · 2024: $126 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,268 · Honoraria: $259 · Food and Beverage: $219 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,267.50 |
| Honoraria | $259.36 |
| Food and Beverage | $218.90 |
| Education | $115.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,876.23 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $2,750.00 | 2021 | |
| Hema Biologics, LLC | $2,514.78 | 2021 | |
| Baxter Healthcare | $2,425.00 | 2019 | |
| Gilead Sciences, INC. | $2,315.63 | 2019 | |
| Beigene USA, INC. | $1,967.32 | 2023-2024 | Brukinsa |
| Genzyme Corporation | $1,825.00 | 2019-2021 | |
| Tg Therapeutics, INC. | $1,526.25 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,375.00 | 2025 | |
| Csl Behring | $1,009.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $950.00 | 2019 | |
| Tersera Therapeutics LLC | $453.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $351.00 | 2021 | |
| Karyopharm Therapeutics INC. | $271.49 | 2025 | Xpovio |
| Seagen INC. | $87.05 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $83.13 | 2021-2023 | Pomalyst, Opdivo |
| Pfizer INC. | $73.80 | 2019-2024 | |
| Aveo Pharmaceuticals, INC. | $51.63 | 2022-2023 | Fotivda |
| Lilly USA, LLC | $40.36 | 2019-2020 | |
| Incyte Corporation | $37.91 | 2024 | Pemazyre |
| Amgen INC. | $37.70 | 2020 | |
| Exelixis INC. | $27.55 | 2019 | |
| Immunocore Limited | $23.60 | 2024 | Kimmtrak |
| Stemline Therapeutics INC. | $16.58 | 2021 | |
| Fresenius Kabi USA, LLC | $16.34 | 2023 | |
| Genentech USA, INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Bach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.